

Non-Personal Promotion (NPP) to HCPs: A Comprehensive Guide for Pharma Marketers

By Adrien Laurent, CEO at IntuitionLabs • 4/13/2025 • 40 min read

non-personal-promotion

npp

hcp-engagement

pharma-marketing

digital-marketing

healthcare-compliance

fda-regulations

pharma-code

omnichannel-marketing



[Revised January 11, 2026]

Non-Personal Promotion (NPP) to HCPs: A Comprehensive Guide for Pharma Marketers

Non-Personal Promotion (NPP) has become a cornerstone of pharmaceutical marketing to healthcare professionals (HCPs) in the United States. With traditional sales rep access to physicians limited and digital engagement on the rise, pharma marketers and sales teams are leveraging NPP to reach HCPs at scale in a compliant, cost-effective way ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)) ([More Than Half US Physicians Place Moderate-to-Severe Restrictions on Pharma Sales Reps](#)). This article defines NPP, explores its value in modern pharma marketing, outlines best practices for executing NPP campaigns, summarizes key U.S. compliance requirements (FDA regulations, PhRMA Code, state laws), and lists common tools that enable successful NPP strategies. For more information on pharmaceutical marketing strategies, see our articles on [Veeva PromoMats](#) and [Veeva Vault](#).

What Is NPP and Why It Matters in Pharma Marketing

Definition: Non-Personal Promotion refers to marketing strategies that engage HCPs **without real-time, personal interaction** from a sales rep ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). In practice, NPP means delivering promotional messages through one-to-many channels (e.g. mass emails, mailed materials, digital ads) that are pre-approved and automated, rather than one-on-one communication. The messaging is consistent across recipients and does not require immediate human dialogue ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). Essentially, NPP is any promotional activity targeted at HCPs that does not involve face-to-face or live personal selling.

Role and Value: NPP has surged in importance due to shifts in the healthcare landscape. Pharmaceutical companies face **declining access** to physicians via traditional reps – approximately half of U.S. physicians place moderate-to-severe restrictions on rep visits, with physicians becoming increasingly selective about which companies they engage with ([More Than Half US Physicians Place Moderate-to-Severe Restrictions on Pharma Sales Reps](#)). Currently, half of accessible HCPs meet with three or fewer companies, and nearly 30% in specialties such as internal medicine, oncology, psychiatry, and urology restrict access to just one company ([HCP Engagement Trends 2025](#)). This trend was exacerbated by the COVID-19 pandemic, when in-person access plummeted to ~20% of pre-pandemic levels. While access has partially rebounded to around 60% according to Veeva's Pulse Field Trends Report, the shift toward hybrid engagement (combining in-person and virtual interactions) has become permanent ([Report suggests bounce-back in rate of pharma-friendly docs](#)). At the same time, the **cost of large sales forces** and **HCP preference for digital communication** have driven adoption of NPP ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). Over 70% of physicians now use smartphones or tablets for professional purposes, making mobile-optimized NPP content essential. NPP allows pharma brands to maintain **consistent messaging across many touchpoints** and to reach “no-see” doctors in **white-space territories** where reps can't visit ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). When executed effectively, NPP is a **scalable, cost-efficient** way to keep HCPs informed and engaged between or in lieu of rep visits. For example, overall healthcare marketing spend is rising partly due to growth in digital outreach and NPP tactics as companies seek cost-effective HCP engagement amid competition ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). In short, NPP complements personal promotion by extending reach, reinforcing brand messages, and providing on-demand information to busy clinicians.

Key NPP Channels: NPP encompasses both **digital and traditional** media used to reach HCPs without personal interaction. Common NPP channels include:

- **Email marketing:** Mass distribution of approved promotional emails or e-newsletters to HCPs. Email remains one of the most preferred channels for physicians – **78% of HCPs rank email as their favored way** to receive medical updates ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). Well-crafted emails enable HCPs to consume content on their own schedule and can efficiently reach thousands of targets at once.
- **Digital advertising:** Online ads targeted to HCP audiences, such as banner ads on medical websites, programmatic ads on physician networks, and social media campaigns on professional platforms. These allow repeated, consistent exposure to brand messages where HCPs already browse online ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). For instance, an HCP might see a drug's banner ad while reading a journal online, reinforcing awareness.
- **Direct mail:** Physical mailers (e.g. brochures, dosing guides, reprints of journal articles) sent to HCP offices. Despite digital growth, printed materials are still an effective NPP tactic ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). Direct mail provides a tangible resource that HCPs can read at their convenience and is useful for reaching those who prefer or respond to offline media.
- **On-demand content:** Educational or promotional content that HCPs can access digitally on their own, such as webinars, pre-recorded product demos, online CE modules, or whitepapers. Providing valuable on-demand resources (e.g. an on-demand webinar about a disease state) positions the company as a **thought leader** while delivering key product information in a non-intrusive way ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)).
- **Automated follow-ups:** Trigger-based communications sent after certain events or actions. For example, after an HCP attends a virtual speaker program or meets with a rep, a follow-up email or mailed summary can be automatically sent via the CRM. These standardized follow-ups reinforce messages without relying on additional live contact ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). They help extend the impact of personal interactions through non-personal channels.

By leveraging these channels in concert, pharma marketers can create an “**always-on**” presence for their brand. NPP keeps HCPs informed about new data, indications, or patient resources even when reps are not there in person, which is especially valuable as HCPs increasingly engage through digital means.

Best Practices for NPP Campaigns Targeting HCPs

Executing a successful NPP campaign requires strategic planning and thoughtful execution. The following best practices can help ensure NPP efforts are effective, engaging, and well-received by healthcare professionals:

1. Strategic HCP Segmentation and Targeting

Not all HCPs are the same – segmenting your target audience is fundamental. **Divide HCPs into meaningful segments** based on factors such as specialty, practice setting, prescribing habits, geographic region, and communication preferences ([The Non-Personal Promotion Equation](#)). For example, a cardiologist in a hospital might need different messaging than a primary care physician in private practice. Use both internal data (e.g. prescribing or sales data) and external data (professional databases, medical claims, etc.) to inform your segmentation.

Prioritize high-value targets: Focus NPP efforts on HCPs who are most relevant to your brand's therapeutic area and business goals. This may include high-prescribers in the drug's category, HCPs with a large patient population of interest, or those in “white space” regions with no reps. By identifying the right targets, you ensure NPP resources are spent efficiently on the HCPs most likely to benefit from your information ([The Non-Personal Promotion Equation](#)). As one pharma strategy contributor notes, “*It's crucial to focus on the right physicians... consider factors such as NPs/PAs that support your physician targets, and even office staff that influence decisions*” ([The Non-Personal Promotion Equation](#)). In practice, this could mean expanding targeting beyond MDs to include allied HCPs if they impact prescribing.

Tailor content to segments: Once segments are defined, customize the content and channel mix for each group. For instance, new-to-practice physicians might get basic educational materials and starter kits, while experienced specialists receive detailed clinical study data. Segmentation should also guide channel selection – if one segment (e.g. nurse practitioners) responds better to webinars than email, adjust accordingly. Overall, segmentation enables a more precise and relevant NPP approach rather than a one-size-fits-all blast.

2. Personalization – Making “Non-Personal” Outreach More Personal

Even though NPP is “non-personal” in terms of delivery, the content should feel **personalized and relevant** to each HCP. Busy physicians are inundated with promotional messages and will tune out anything irrelevant ([The Non-Personal Promotion Equation](#)). To capture attention, tailor your messaging as much as possible:

- **Use personalization tokens:** Where permitted, address HCPs by name and reference their specialty or practice in communications. For example, an email might open with “*Dear Dr. Smith, as a cardiologist, you may be interested in...*” This simple personalization can increase engagement, as it shows the content is meant for their specific context.
- **Leverage preferences and behavior:** If you have data on an HCP’s past engagements (e.g. they clicked on a certain article or visited your booth at a conference), use that to customize follow-up content. Modern NPP platforms and AI allow for **dynamic content** that can insert different images or messages based on recipient attributes ([Embracing Programmatic Advertising to Enhance Targeting of HCPs](#)). For instance, if a doctor previously showed interest in safety data, your next email can highlight safety profile information. This makes the outreach feel more one-to-one.
- **Relevant content is key:** Ultimately, personalization is about **relevance**. HCPs will engage “only with those brands who present the most relevant content” to their needs ([The Non-Personal Promotion Equation](#)). Successful NPP “must serve the customer at the individual level” even without a personal interaction ([The Non-Personal Promotion Equation](#)). That means providing information that aligns with each physician’s clinical interests and patient population. For example, a dermatologist will respond better to a case study in dermatology than a general mechanism-of-action piece. By aligning content to what matters to that segment or individual, you make non-personal outreach feel more personal and valuable.

One caution: ensure that personalization efforts stay within compliance boundaries. Avoid using any personal health information or overly granular data that could raise privacy concerns (discussed under compliance below). Focus on professional personalization (specialty, past professional interactions) rather than personal details.

3. Compelling Content and Message Optimization

In NPP, **content is king** – without a rep to add a personal touch, the materials themselves must drive engagement. Best practices for NPP content include:

- **Keep it concise and focused:** Physicians have limited time. Whether it’s an email, mailer, or banner ad, get to the point quickly with clear, succinct messaging. Highlight the key benefit or information up front. For emails, subject lines and headers should immediately signal the value (“New clinical data on [Drug] – 2-minute update”). In printed pieces, use headlines, bullet points, and visuals to make content scannable.
- **Provide educational value:** NPP materials should not only promote the product but also **educate or inform**. HCPs respond better to content that helps them in practice (e.g. disease insights, treatment guidelines, patient education tools) rather than pure sales pitches. Even promotional pieces should include clinically relevant information or practice tips. For example, an email could share a new study result or a dosing chart that the physician might find useful. By adding value, you build trust and engagement.
- **Optimize format for channel:** Tailor content format to the channel. Emails and websites should be mobile-friendly given many HCPs check email on smartphones. Short video clips or interactive infographics can work well for on-

demand content. Mailed print pieces might use high-quality visuals and call-out boxes knowing they'll be read offline. Ensure any digital content loads fast and is compatible with common browsers and devices used in medical settings.

- **Test and refine:** Treat NPP content as an evolving effort. Use A/B testing where possible (e.g. try two different subject lines or layouts with small segments of your list) to see which version performs better, then roll out the winner more broadly. Monitor engagement metrics closely – open rates, click-throughs, time on page, etc. These **key performance indicators (KPIs)** will show what resonates. For instance, if an email's click rate is low, the content or call-to-action might need tweaking in future sends ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). Continuously refine content based on data and HCP feedback. Some campaigns set up a feedback channel (like a brief survey link) to directly get HCP input on what content they want more of.
- **Ensure medical and regulatory accuracy:** All NPP content must go through proper medical, legal, regulatory (MLR) review. Best practice is to have an **approved content library** and stick to it – this avoids compliance slip-ups (more on compliance later). Additionally, content should be **factually accurate and on-label** for the product. Never exaggerate claims or omit important risk information. Consistency and integrity in messaging across all NPP materials not only keep you compliant but also maintain credibility with HCPs.

By optimizing content for relevance, clarity, and value, pharma marketers can significantly improve HCP engagement with NPP. Remember, without a rep in the room, your content carries the full weight of the communication – so invest in making it excellent.

4. Multichannel Integration and Orchestration

NPP works best as part of an **omnichannel strategy**. Rather than using each channel in isolation, integrate multiple channels to create a seamless experience for HCPs. Key practices for multichannel orchestration include:

- **Coordinate messaging across channels:** Ensure that your email, direct mail, ads, and other touchpoints are aligned in message and timing. HCPs should receive a **consistent story** about your product, regardless of channel ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). For example, around a new indication launch, you might send an email announcement, display banner ads on a medical news site, and mail a clinical brochure – all carrying the same core message and branding. This repetition through different media reinforces recall. An integrated approach prevents confusion that could arise if one channel lags or contradicts another.
- **Sequence touchpoints for maximum impact:** Plan the *order* and *timing* of channel touches to complement each other. One proven tactic is to use NPP to **prime or follow up** on personal visits. For instance, a rep visit can be preceded by an introductory email, and followed by a thank-you email with additional resources triggered automatically via CRM ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)) ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)). A compliant example of orchestration: a rep details a physician, then the physician later sees a banner ad on a medical journal site reinforcing the same message, and perhaps receives a direct mail packet the next week with deeper clinical data – all connected elements of one campaign. This synchronized approach (“surround sound” marketing) keeps the brand top-of-mind. One pharma omnichannel expert describes it as ensuring “none of these touchpoints operate in isolation” – each is informed by the HCP's prior engagements and is part of a cohesive journey ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)).
- **Use the right channel for the right message:** Different channels have different strengths. Use email or mail for delivering detailed information (e.g. clinical study reprint), use digital ads for quick reminders or brand awareness, use webinars or videos for demonstrating complex concepts. If launching a new mode of action video, an email might invite HCPs to view it, and then retargeted ads could remind them later. Align channel choice with the content purpose and the HCP's preference. Some HCPs might ignore emails but pay attention to mail; others prefer digital only – so multichannel ensures you cover all bases.

- **Frequency capping and preference management:** While multi-touch is valuable, be careful not to overwhelm HCPs. Coordinate frequency so that an HCP isn't, say, getting an email every day plus constant ads – too much contact can lead to annoyance or opt-outs. Using a CRM or marketing automation system, set rules (e.g. no more than X emails per month to a given HCP, etc.). Also, **respect opt-outs and channel preferences** – if an HCP unsubscribes from emails or indicates they prefer mail only, honor that across all systems. A well-integrated approach will include governance to prevent over-communication, which not only is good practice but also a compliance safeguard (avoiding allegations of spamming or improper use of contact info).
- **Track and adjust in real-time:** Integration isn't just in planning, but also in measurement. Use integrated analytics to see the full picture of HCP engagement across channels. For example, your CRM should log that Dr. Jones received an email, clicked a link, then later visited a microsite, etc. Monitoring these journeys helps you identify what sequence works best or where drop-offs occur. Perhaps you find that HCPs who receive a mailer after an email have a higher follow-up meeting rate – that insight can refine future planning. Integrated data allows for “next-best-action” algorithms too, where based on an HCP's recent actions, the system suggests the next channel touch (e.g. if they never opened emails but did visit a website, maybe schedule a rep call or send a mailer). Leading companies are using AI in their omnichannel engines to optimize such cross-channel engagement, while ensuring all content pushed is compliant and pre-approved ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)) ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)).

Overall, multichannel integration makes NPP significantly more powerful. By orchestrating email, digital, print, and personal channels in harmony, pharma marketers create an **omnichannel experience** that meets HCPs wherever they prefer to engage. The result is greater reach and impact – one channel's message reinforces another, improving recall and action. In today's environment, an “**all of the above**” approach (personal + non-personal together) is often the most effective way to ensure your brand's message breaks through the noise ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)).

(Tip: Consider mapping out the HCP journey with all touchpoints on a timeline to visualize your omnichannel plan. This helps identify any gaps or overloads in the sequence.)

5. Monitoring, Measurement, and Continuous Optimization

No NPP campaign should be “launch and forget.” **Measuring results and optimizing** based on data is crucial for sustained success. Start by defining clear **Key Performance Indicators (KPIs)** for your NPP initiatives ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)). Common KPIs in HCP NPP campaigns include email open and click-through rates, website or portal traffic from HCPs, time spent on content (e.g. webinar attendance duration), conversion actions (such as an HCP requesting samples or scheduling a meeting), and of course, downstream impact on new prescriptions or formulary wins (where measurable).

Track engagement across channels: Use integrated analytics tools or dashboards (often tied into your CRM or marketing automation platform) to monitor these metrics in real time. For instance, track how many physicians opened the last email blast, which links were clicked most, how many visits your product website got after a direct mail drop, etc. By correlating engagement data, you can see what's working. If one channel underperforms (say, low email opens in a segment), you might try adjusting send times or subject lines, or reinforcing via another channel.

A/B test and iterate: Embrace an agile mindset of continuous improvement. Test small variations in your approach – for example, send two versions of an email to sub-samples (different subject line or call-to-action) to see which performs better, then use the winner for the broader audience. Over time, even incremental gains in open rate or click rate compound into significantly more engagement. Similarly, pilot new channels or content formats with a test group of HCPs before scaling up. Always document learnings and apply them to the next campaign or wave. NPP is an ongoing cycle of execution, measurement, and refinement.

Connect to outcomes: Whenever possible, link your NPP engagement metrics to ultimate business outcomes like new prescriptions, formulary uptake, or changes in HCP awareness and intent (perhaps via surveys). While it's often hard to attribute sales impact to specific marketing touches, data integration can help. For example, you might find that HCPs who engaged with at least two NPP touchpoints were X% more likely to prescribe your drug – a powerful insight to justify the NPP investment. Establishing this **feedback loop** not only justifies the NPP program's ROI but also guides budget allocation (invest more in the tactics that drive results).

In summary, treat NPP campaigns as living programs. By diligently tracking performance and being willing to adjust strategy (e.g. refining segments, tweaking content, rebalancing channel mix), pharma marketers can continuously improve their NPP effectiveness and better serve HCP customers' needs.

Key U.S. Regulations and Compliance Requirements for NPP

Marketing to HCPs in the U.S. is heavily regulated to ensure promotions are truthful, balanced, and ethical. Non-personal promotion must adhere to the same rules as other pharma promotional activities. Here we summarize the key compliance frameworks – FDA regulations, the PhRMA Code, and relevant federal/state laws – that pharma marketers need to follow when executing NPP:

FDA Advertising and Promotion Rules

The U.S. Food and Drug Administration (FDA) regulates prescription drug advertising and promotional labeling, regardless of channel. **Any promotional material aimed at HCPs must be FDA-compliant.** Important FDA requirements include:

- **Truthful, non-misleading information:** All claims about a drug's efficacy or safety must be truthful and supported by substantial evidence. You cannot promote uses not approved in the official prescribing information (no "off-label" promotion).
- **"Fair balance" of risks and benefits:** FDA regulations require that product promotions present a **balanced view of risks and benefits** ([Drug Advertising: A Glossary of Terms - FDA](#)). This means if you discuss a drug's benefits (efficacy, indications), you must give comparable prominence to its important risks (contraindications, side effects). For example, an email or brochure that touts efficacy must also include or link to safety information. In digital formats, providing a clear link or popup with **Important Safety Information (ISI)** and directing HCPs to full Prescribing Information is standard practice to meet this requirement.
- **Required disclosures:** All promotional labeling for HCPs should include the drug's **brand and generic name**, its approved use, and often a statement like "See full Prescribing Information" or attach the prescribing information (for print). Journal ads or print materials often need the FDA-required **brief summary** of risk information or PI attached ([Drug Advertising: A Glossary of Terms - FDA](#)) ([Drug Advertising: A Glossary of Terms - FDA](#)). For email, a footer with important safety info and a link to PI is typical. If space is limited (e.g. a small banner ad), FDA guidance allows for a "reminder ad" (no claims, just name) or requires a click-through to risk info. Always ensure digital ads comply with FDA's internet promotion guidances – e.g., avoid making claims on Twitter-length posts that can't accommodate risk info.
- **No pre-approval promotion:** You cannot promote a drug before it is FDA-approved. Even **"coming soon"** notifications are restricted to just the name and that approval is pending, without any efficacy or safety claims ([Link](#)) ([Link](#)). Ensure NPP campaigns only promote on-label information for approved products.
- **OPDP oversight:** The FDA's Office of Prescription Drug Promotion (OPDP) monitors promotional materials (including emails, websites, ads). Companies must submit many promotional pieces to OPDP at first use (Form 2253 submissions). Violations (e.g. misleading claims, off-label promotion, lack of fair balance) can result in FDA warning letters or penalties. **"Bad Ad" Program:** FDA even encourages HCPs to report misleading drug ads through its "Bad

Ad” program ([The Bad Ad Program - FDA](#)). So, maintaining compliance in NPP not only avoids regulatory trouble but also protects the company’s reputation among the medical community.

September 2025 FDA Enforcement Initiative: On September 9, 2025, the FDA launched one of its most aggressive enforcement initiatives in decades, targeting deceptive pharmaceutical advertising practices across television, digital platforms, and social media. The agency delivered over 100 cease-and-desist letters and issued thousands of warning letters demanding immediate compliance ([FDA Cracks Down on DTC Advertising](#)). Key proposed changes include:

- **Elimination of the “adequate provision” loophole:** The FDA is initiating rulemaking to rescind the provision that allowed manufacturers to include a general risk statement alongside a webpage link or 1-800 number instead of full disclosure. This would require key safety disclosures (boxed warnings, contraindications) to appear directly within advertisements.
- **Enhanced social media oversight:** With nearly 50% of pharmaceutical digital advertising budgets now allocated to social media channels, the FDA announced expanded oversight of prescription drug advertising on these platforms ([Pharmaceutical Advertising Laws 2025-2026](#)).
- **AI-powered surveillance:** The FDA has indicated plans to employ artificial intelligence and other digital tools to enhance its surveillance capabilities for detecting non-compliant promotional materials.

These updates reinforce that digital promotion is not a regulatory loophole – it is subject to the same rigorous standards as traditional print and broadcast advertising. Pharma marketers should ensure all NPP content, especially digital and social media materials, meets enhanced disclosure requirements.

In short, treat every NPP asset as if it were a detail aid in a rep’s hands – it must be **accurate, balanced, and consistent with the label**. Work closely with Medical/Legal/Regulatory review committees to approve all content before dissemination. And remember, FDA rules apply equally to digital media as to print – there’s no leniency for an email versus a brochure when it comes to ensuring promotional statements are properly qualified and balanced.

PhRMA Code and Industry Ethical Guidelines

Beyond FDA law, the U.S. pharmaceutical industry abides by self-regulatory standards, chiefly the **PhRMA Code on Interactions with Health Care Professionals**. This code, established by the Pharmaceutical Research and Manufacturers of America, sets the **ethical norms** for pharma marketing practices toward HCPs. While voluntary, it is widely adopted and often enforced indirectly (many companies incorporate it into policy, and some state laws reference it).

Key PhRMA Code principles relevant to NPP include:

- **No lavish or non-educational gifts:** The PhRMA Code **prohibits pharmaceutical reps from giving even modest gifts to physicians if they don’t serve an educational purpose** ([PhRMA Code on Interactions - McGuireWoods](#)). Items like logo-branded pens, mugs, or trinkets – once common giveaways – are no longer allowed ([PhRMA Code on Interactions - McGuireWoods](#)). The only acceptable “gifts” are items **for education or patient benefit**, usually under \$100 in value (e.g. medical textbooks, anatomical models for the office) and even those only occasionally ([PhRMA Code on Interactions - McGuireWoods](#)). For NPP, this means any direct mail item or promotional swag must have bona fide educational value. Simply sending branded merchandise (coffee mugs, calendars, etc.) would violate industry ethics.
- **Meals restrictions:** The code bans company-paid dinners or entertainment for HCPs unrelated to an educational presentation ([PhRMA Code on Interactions - McGuireWoods](#)). Sales reps cannot take doctors out for lavish meals or sporting events as inducements. Only **“modest” meals in a clinical setting** (like sandwiches in the office during an educational lunch-and-learn) are permitted, and the rep should be present to provide info ([PhRMA Code on Interactions - McGuireWoods](#)). For NPP campaign planning, this means you wouldn’t organize an expensive dinner seminar as purely promotional (and if you do any sponsored lunch, it must stick to modest cost and educational

content). Many NPP tactics avoid meals altogether, but if, say, a mailed invitation offers a meal at a program, it must comply with these limits.

- **No cash or equivalent rewards for attending promos:** Offering honoraria or payments to HCPs just for listening to a promotional presentation is against the code. Avoid any NPP tactic that offers gift cards, personal rewards, or other compensation to HCPs for engaging with promotional content. (Paying speakers or consultants for bona fide services is allowed, but that's a different scenario and comes with disclosure requirements.)
- **Focus on informational content:** The spirit of the PhRMA Code is that interactions with HCPs should be **informative and patient-care focused**, not inducements. This means NPP content should genuinely help HCPs make informed decisions. For example, providing a clinical reprint with an objective study is encouraged (if approved through MLR), whereas a flashy promotional flyer with minimal substance might be frowned upon. Always aim to **“provide accurate, not misleading, science-based information”** in line with the Code's intent.
- **Speaker programs and training:** The Code also covers standards for speaker programs and other promotional education events (e.g., slide decks must be ethical, any hospitality very limited, attendees shouldn't be just friends/family of the speaker, etc.). If your NPP includes inviting HCPs to webinars or dinner talks, be sure to follow these guidelines. Recent updates to the Code (2022) put even more scrutiny on speaker programs (e.g. discouraging expensive venues or alcohol at events) ([PhRMA Code Revisions to Go Into Effect January 2022](#)) ([PhRMA Code Revisions to Go Into Effect January 2022](#)).

While NPP tactics (like emails and mailers) might seem removed from rep conduct, **the same ethical standards apply**. For instance, if you mail an “educational” item, ensure it truly is educational and modest in value. If you are inviting HCPs to a sponsored webcast, keep the tone educational, not just a sales pitch with fancy production. Adhering to the PhRMA Code helps maintain trust and avoids unwanted attention from enforcement bodies or the media. Importantly, many hospitals and academic centers only allow interactions that meet PhRMA Code standards, so violating these could get your company barred from certain institutions.

Federal and State Laws (Sunshine Act, Gift Bans, Privacy)

Sunshine Act (Open Payments): Under the federal Physician Payments Sunshine Act (part of the Affordable Care Act), pharmaceutical manufacturers must **track and annually report any payments or transfers of value to physicians and certain other HCPs**. This includes consulting fees, speaker honoraria, meals, travel, and even small items if over \$10 (or multiple small items totaling over \$100 per year) for a covered recipient. The data is made public in the CMS Open Payments database. For NPP, pure digital promotions (like an email or ad) generally do *not* involve reportable “transfers of value.” However, if your NPP campaign provides something of value – e.g., you send a textbook (~\$80) to targeted physicians or pay for their lunch during a webcast – those are reportable. Marketers must coordinate with compliance teams to ensure any such spend is properly captured for Sunshine reporting. The Sunshine Act doesn't prohibit the payments, but the public disclosure incentivizes companies to avoid anything that could appear as undue influence.

State marketing laws: Several states have enacted their own laws that go beyond the PhRMA Code, imposing stricter rules on pharma-HCP interactions:

- **Vermont:** Vermont has one of the strictest laws, essentially a **ban on most gifts and meals to HCPs**. The law *“prohibits drug and device manufacturers from offering any payment, food, entertainment, travel, or anything of value to a health care provider for free,”* with only very limited exceptions (like samples or educational materials) ([Vermont Expands Physician Gift Ban and Disclosure Policy to Apply to Device Manufacturers - McGuireWoods](#)) ([Vermont Expands Physician Gift Ban and Disclosure Policy to Apply to Device Manufacturers - McGuireWoods](#)). Vermont also requires all allowable expenditures to be disclosed to the state. In practice, companies treat Vermont HCPs with extreme care – usually no meals, no gifts, and only educational mailings allowed. If your NPP list includes Vermont prescribers, you must filter out any prohibited activities (e.g. don't send a gift or offer a gift card to a Vermont doctor; even a modest journal reprint might need to be reported).

- **Massachusetts:** Massachusetts law (since 2009) requires manufacturers to adopt a state **marketing code of conduct** consistent with PhRMA Code and to **disclose payments** \$50 or greater to HCPs ([Regulations on Gifts from Drug Companies - Mass.gov](#)). It also bans gifts like restaurant meals or entertainment. Basically, Massachusetts codified the PhRMA Code into law and added a state reporting requirement. Ensure any NPP spending (like providing an educational item or sponsored meeting) for MA-licensed HCPs is compliant and reported. Massachusetts also mandates companies have training and compliance programs in place – so NPP tactics should be part of your internal compliance training.
- **Other states:** A few other states have notable rules. **Minnesota** bans annual gifts over \$50 to practitioners (similar to a cap). **New Jersey** implemented regulations capping meal values (e.g. ~\$15 for breakfast/lunch, \$30 for dinner for in-office programs) and limiting annual compensation for NJ prescribers. **California** requires companies to set an annual dollar limit on gifts to HCPs and adhere to it (often companies set it at \$0 or a very low amount given PhRMA Code already bans gifts). While these vary, the common theme is additional scrutiny on anything that could be seen as a kickback or excessive. Marketers should work closely with compliance to navigate the patchwork of state laws when planning nationwide NPP campaigns. Often the safest route is to apply the strictest common denominator (e.g. no gifts, modest in-office meals only) across all states, which aligns with PhRMA Code anyway.

Privacy laws (HIPAA, CCPA, etc): NPP often involves handling HCP contact information and sometimes patient data analytics for targeting. Compliance with privacy regulations is vital:

- **HIPAA:** The Health Insurance Portability and Accountability Act primarily protects patient health information. Generally, marketing to HCPs using their professional contact info does not involve HIPAA, as you're not using patient data. **However**, if any patient data or PHI is used in segmentation (for example, targeting doctors based on their patient population or using identifiable patient cases in communications), then HIPAA could be implicated. Ensure any patient data is de-identified unless you have proper authorization. As a rule, NPP campaigns should stick to **non-patient-identifiable data**. Also, refrain from including any patient identifiers if HCP communications discuss cases. HIPAA breaches can lead to severe penalties and erode HCP trust.
- **CAN-SPAM Act:** For email promotions, the CAN-SPAM law applies. This is a federal law governing commercial email. Key requirements: always include a clear **opt-out/unsubscribe** mechanism in every marketing email, honor opt-outs promptly, and include the sender's physical mailing address in the email. The subject line should not be deceptive. While CAN-SPAM isn't specific to pharma, compliance is mandatory. Most pharma companies route HCP marketing emails through systems that handle these automatically (footer with unsubscribe link, etc.). Ensure your email vendor or system is configured to meet CAN-SPAM standards for every blast.
- **CCPA/CPRA (California Consumer Privacy Act) and other data laws:** California law gives individuals (including HCPs as individuals) rights over their personal data. As of 2023, California's CPRA covers **business-to-business contacts** as well, which means a physician's work email or info could be considered personal data. If you're using personal identifiers, you may need to allow California HCPs to opt-out of "sale" of their data (if, for instance, you obtained their contact from a third-party list) and disclose what data you collect. In practical terms, include a privacy notice in your digital communications and honor any data-related requests. Other states (like Colorado, Virginia) have similar privacy laws coming online. **Ensure your HCP databases and marketing practices comply with relevant privacy regulations** – e.g. only use licensed HCP lists from reputable sources, secure consent where required, and don't misuse personal data. As noted earlier, even advanced targeting like AI-driven segmentation must handle data carefully under laws like CCPA and GDPR ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#)).
- **Telephone/SMS marketing:** If your NPP were to include texting HCPs or automated calls (which is rare in HCP marketing but possible for say event reminders), remember the Telephone Consumer Protection Act (TCPA) requires prior consent for marketing texts/calls to cell phones. Always get explicit opt-in if using SMS as a channel for HCPs.

Why compliance matters: Aside from avoiding legal penalties (FDA warning letters, state fines) and lawsuits, following these regulations preserves your company's integrity. HCPs are generally aware of promotion guidelines; overt violations can damage your reputation with your audience. A compliant NPP program means HCPs get high-quality, truthful

information and have transparency into any exchanges of value – which ultimately fosters trust. In planning NPP, always involve your Regulatory and Compliance teams early. Build **compliance checkpoints** into content development, deployment, and data handling. As one expert puts it, “*compliance must be built into the omnichannel architecture from the ground up*” ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)). By doing so, you can innovate in NPP while staying within the guardrails of U.S. laws and ethical standards.

Tools and Platforms Supporting NPP in Pharma

Implementing NPP at scale requires robust tools and technology. Fortunately, there are many software platforms and services tailored to pharmaceutical marketing that can help execute NPP campaigns efficiently and compliantly. Below are some commonly used tools and categories of platforms that support NPP activities (note: specific product names are examples, not endorsements, and there is overlap in capabilities across platforms):

- **Customer Relationship Management (CRM) Systems:** A good CRM is the backbone of coordinated HCP engagement. The pharma CRM landscape is undergoing significant transformation in 2025-2026. **Veeva CRM** has long been the market leader with approximately 80% global market share, but is now transitioning to **Veeva Vault CRM**, moving away from its Salesforce foundation. Veeva CRM on Salesforce entered “stability mode” in September 2025 and will be supported until 2030, but without new features ([IQVIA vs Veeva CRM Comparison 2025](#)). **IQVIA OCE (Orchestrated Customer Engagement)** serves approximately 400 customers in 130+ countries and offers AI-powered next-best-action recommendations via its embedded assistant. In 2024, Salesforce partnered with IQVIA to launch **Salesforce Life Sciences Cloud for Customer Engagement**, which reached general availability in October 2025, creating a third major player in the market. These systems log both rep visits and non-personal touches, giving a unified view of the customer. CRM integration allows reps and marketers to see what emails or mailings a doctor has received, schedule automated follow-ups, and maintain consistency. CRM systems often have built-in compliance rules (e.g. frequency caps, content approvals) to ensure outreach stays within guidelines. In short, CRM is the hub that connects all channels and teams, enabling true omnichannel NPP execution. *Note: Companies using Veeva CRM should be planning their migration strategy now, as the peak migration period is expected between 2025-2027.*
- **Email Marketing & Marketing Automation:** For deploying mass emails to HCPs (while personalizing at scale), pharma companies use specialized email marketing platforms. Some CRM suites (like Veeva or Salesforce Marketing Cloud) include approved email functionality. In addition, third-party services such as **IQVIA's email distribution platforms or DMD Connects** offer large databases of opted-in HCP emails and targeting capabilities ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)). These platforms allow segmentation of physician audiences by specialty, geography, prescribing behavior, etc., and can send tailored email campaigns with tracking. Key features to look for are: integration with your CRM (to avoid duplicates or conflicting messaging), strong permission management (opt-outs, preferences), and MLR approval workflows for content. **Marketing automation** software (like Marketo, Oracle Eloqua, etc.) is also used to create automated email nurture streams – for example, sending a sequence of introduction, follow-up, and reminder emails based on if the HCP opens or clicks. Choose tools that can handle the scale of your list and comply with healthcare data privacy (some general email tools like MailChimp might not have built-in HCP list management or may not sign a Business Associate Agreement if needed; in contrast, industry-focused providers address these needs).

- **Programmatic Advertising Platforms:** Programmatic advertising refers to automated, data-driven buying of digital ad placements. In the HCP marketing realm, several **healthcare-specific demand-side platforms (DSPs)** and networks exist. For instance, platforms like **DeepIntent** and **Doceree** are designed specifically for pharma, allowing you to serve digital ads (banner, video) to HCPs with precision targeting. DeepIntent offers the Health Advertising Platform with privacy-compliant, omnichannel solutions and AI-driven optimization, featuring a comprehensive HCP identity graph for maximum reach and accuracy ([DeepIntent Healthcare Marketing Platform](#)). Doceree positions itself as an AI-powered operating system for healthcare marketing and recently launched **Premium Programmatic**, enabling engagement across 2,000+ integrated specialist medical platforms with deterministic HCP identification ([Doceree Premium Programmatic](#)). These platforms use identifiers like the physician's National Provider Identifier (NPI) or demographic data to target ads only to licensed HCPs on professional websites. Additionally, companies like **PulsePoint (WebMD)** and **HealthLink Dimensions** provide programmatic solutions to reach verified HCPs across medical web properties. With 72% of new drug approvals now in rare disease, the ability to precisely reach small, complex patient populations is becoming the next frontier in programmatic HCP marketing. With programmatic, you can ensure your banner or display ads are seen only by relevant HCP audiences (e.g. oncologists) as they browse the web. These platforms typically offer analytics on impressions, clicks, and can integrate with your CRM to link ad exposure to specific HCP profiles. When using programmatic ads, it's crucial to supply compliant ad creatives (with required safety info in ad or landing page) and to set frequency limits. Programmatic advertising has become popular because it offers **scale and personalization** – for example, an AI-enabled DSP might customize the ad content shown to different HCP segments automatically ([Embracing Programmatic Advertising to Enhance Targeting of HCPs](#)). It's a powerful tool to include in NPP, ensuring your brand presence across the digital journeys of your target doctors.
- **HCP Engagement Portals and Virtual Event Platforms:** Another category of NPP tools are platforms that host on-demand content or virtual meetings for HCPs. For instance, **webinar and virtual event platforms** (like ON24, Zoom Webinar, or Microsoft Teams) are used to deliver remote educational programs to HCPs at scale. These became especially critical during the pandemic. Companies often integrate these with registration and follow-up email tools to manage invitations and reminders. **HCP community portals** like Medscape, Doximity, or Sermo can also be leveraged: these networks offer channels to post sponsored content or organize discussions around your therapeutic area (within compliance limits). While not traditional “software you buy,” they are platforms where NPP tactics (like sponsored quizzes, banner ads, or email blasts to member physicians) can run. If budget permits, using such professional networks can expand reach since many HCPs regularly use them for news or collegial exchange.
- **Content Management and Approval Systems:** Given the importance of compliance, pharma companies use systems to manage digital assets and ensure only approved content is deployed. Tools like **Veeva Vault PromoMats** or **MedThink Compliance** (for example) store all marketing materials with their approval status. They help in NPP by allowing marketers to pull only the latest, approved content for an email or ad, and by keeping an audit trail of what was sent when. Some systems support **modular content management**, where small chunks of content (claims, images, references) are approved and can be assembled for different channels on the fly – enabling personalization while still using pre-approved components ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)). Investing in a good content management and digital asset management tool streamlines the MLR review process and avoids the risk of rogue or outdated content being accidentally used in an NPP campaign.
- **Analytics and Reporting Tools:** To measure NPP performance, analytics tools are essential. These range from web analytics (e.g. Google Analytics or Adobe Analytics for your HCP website/landing pages) to email campaign reporting dashboards, to data visualization tools like Tableau or PowerBI that aggregate multi-channel metrics. Many pharma companies also rely on their CRM's built-in reporting or data warehouses that compile HCP engagement data. There are even specialized analytics services from companies like IQVIA or Komodo that can integrate field and NPP data to show a full engagement score per HCP. The tools themselves may not be unique to pharma, but ensuring they are configured for **HCP segmentation** (e.g. reporting by specialty, region, etc.) is key. These platforms help you generate the insights to refine segmentation, content, and channel strategy as discussed in the best practices above.

In summary, a successful NPP operation will typically use a **stack of integrated tools**: a CRM to orchestrate and record interactions, email and advertising platforms to execute outbound communications, content management systems to maintain compliance, and analytics tools to close the loop with data. Many vendors cater specifically to life sciences, offering turnkey solutions compliant with FDA and privacy requirements. For example, one omnichannel scenario might involve: using Veeva CRM to trigger an email via Salesforce Marketing Cloud, buying targeted HCP media through IQVIA's programmatic service, and tracking everything with Veeva CRM analytics – while all content comes from an approved Vault library ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)) ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing - by Justin Kulovsek - Mar, 2025 - Medium](#)). The exact tools will vary by company size and budget, but pharma marketers should leverage these technologies to automate and scale NPP, ensuring each touch is both effective and compliant.

Conclusion: Non-Personal Promotion to HCPs is an increasingly vital part of pharma marketing strategy. By understanding what NPP entails and following best practices – from careful audience segmentation and personalized content, to multichannel coordination and rigorous measurement – organizations can engage healthcare professionals in a meaningful way **beyond the sales rep visit**. Importantly, success in NPP requires navigating a complex compliance environment: all activities must align with FDA rules, ethical codes, and privacy laws to maintain trust and avoid pitfalls. With the right approach and tools, pharma marketers and sales teams can deliver timely, relevant, and compliant information to HCPs at scale, ultimately supporting better-informed clinical decisions and improved patient care. NPP is not about replacing the personal touch, but about **augmenting and reinforcing it** through smart, data-driven outreach. As the industry continues to evolve toward an omnichannel future, mastering NPP will be key for any pharmaceutical brand looking to stay connected with its HCP customers in the U.S. market.

Sources:

1. PDQ Communications – “Non-Personal Promotion (NPP): Examples, Trends & Challenges”, **March 28, 2025** ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#))
2. PharmaVoice – Robert D. Bedford, “Planning and Implementing an Effective Non-Personal Promotion Campaign”, **Aug. 28, 2014** ([Planning and Implementing an Effective Non-Personal Promotion Campaign - PharmaVoice](#))
3. Pharmaceutical Executive – “More Than Half US Physicians Place Moderate-to-Severe Restrictions on Reps”, ZS Associates AccessMonitor report, **Sept 2015** ([More Than Half US Physicians Place Moderate-to-Severe Restrictions on Pharma Sales Reps](#))
4. MM+M – Marc Iskowitz, “The return of rep access”, **Nov 22, 2022** ([Report suggests bounce-back in rate of pharma-friendly docs](#))
5. HealthLink Dimensions – 2024 Physician Communication Report (cited via PDQ) ([Non-Personal Promotion \(NPP\): Examples, Trends & Challenges](#))
6. Pharmaceutical Executive – Barry Winn, “The Non-Personal Promotion Equation”, **Aug 2020** ([The Non-Personal Promotion Equation](#))
7. FDA – Prescription Drug Advertising Guidelines (Fair Balance) ([Drug Advertising: A Glossary of Terms - FDA](#))
8. McGuireWoods – “PhRMA Code on Interactions with Healthcare Professionals”, **July 2008** ([PhRMA Code on Interactions with Healthcare Professionals](#))
9. McGuireWoods Legal Alert – “Vermont Expands Physician Gift Ban...”, **May 22, 2009** ([Vermont Expands Physician Gift Ban and Disclosure Policy to Apply to Device Manufacturers - McGuireWoods](#))
10. Mass. Department of Public Health – Marketing Code of Conduct FAQ, **2009** ([Regulations on Gifts from Drug Companies - Mass.gov](#))
11. Medium (Justin Kulovsek) – “Omnichannel in Pharma: NPP + Field”, **Mar 2025** ([Omnichannel Isn't Just Digital: Why Physical Interactions Still Matter in Pharma Marketing](#))
12. Pharmaceutical Executive – Harshit Jain, “Embracing Programmatic Advertising to Enhance Targeting of HCPs”, **Aug 2023** ([Embracing Programmatic Advertising to Enhance Targeting of HCPs](#))
13. eHealthcare Solutions – “HCP Engagement Trends in 2025: Meeting Physicians Where They Are” ([HCP Engagement Trends 2025](#))
14. McGuireWoods – “As FDA Cracks Down on Direct-to-Consumer and Social Media Ads, Pharma Companies Should Prepare”, **Sept 2025** ([FDA Cracks Down on DTC Advertising](#))
15. ICLG – “Pharmaceutical Advertising Laws and Regulations Report 2025-2026 USA” ([Pharmaceutical Advertising Laws 2025-2026](#))
16. IntuitionLabs – “IQVIA vs Veeva CRM: A Life Sciences CRM Comparison (2025)” ([IQVIA vs Veeva CRM Comparison 2025](#))
17. DeepIntent – “Healthcare Marketing Demand Side Platform” ([DeepIntent Healthcare Marketing Platform](#))
18. Doceree – “DigiPharma Connect 2025” ([Doceree Premium Programmatic](#))

IntuitionLabs - Industry Leadership & Services

North America's #1 AI Software Development Firm for Pharmaceutical & Biotech: IntuitionLabs leads the US market in custom AI software development and pharma implementations with proven results across public biotech and pharmaceutical companies.

Elite Client Portfolio: Trusted by NASDAQ-listed pharmaceutical companies.

Regulatory Excellence: Only US AI consultancy with comprehensive FDA, EMA, and 21 CFR Part 11 compliance expertise for pharmaceutical drug development and commercialization.

Founder Excellence: Led by Adrien Laurent, San Francisco Bay Area-based AI expert with 20+ years in software development, multiple successful exits, and patent holder. Recognized as one of the top AI experts in the USA.

Custom AI Software Development: Build tailored pharmaceutical AI applications, custom CRMs, chatbots, and ERP systems with advanced analytics and regulatory compliance capabilities.

Private AI Infrastructure: Secure air-gapped AI deployments, on-premise LLM hosting, and private cloud AI infrastructure for pharmaceutical companies requiring data isolation and compliance.

Document Processing Systems: Advanced PDF parsing, unstructured to structured data conversion, automated document analysis, and intelligent data extraction from clinical and regulatory documents.

Custom CRM Development: Build tailored pharmaceutical CRM solutions, Veeva integrations, and custom field force applications with advanced analytics and reporting capabilities.

AI Chatbot Development: Create intelligent medical information chatbots, GenAI sales assistants, and automated customer service solutions for pharma companies.

Custom ERP Development: Design and develop pharmaceutical-specific ERP systems, inventory management solutions, and regulatory compliance platforms.

Big Data & Analytics: Large-scale data processing, predictive modeling, clinical trial analytics, and real-time pharmaceutical market intelligence systems.

Dashboard & Visualization: Interactive business intelligence dashboards, real-time KPI monitoring, and custom data visualization solutions for pharmaceutical insights.

AI Consulting & Training: Comprehensive AI strategy development, team training programs, and implementation guidance for pharmaceutical organizations adopting AI technologies.

Contact founder Adrien Laurent and team at <https://intuitionlabs.ai/contact> for a consultation.

DISCLAIMER

The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein.

Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document.

This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it.

All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders.

IntuitionLabs.ai is North America's leading AI software development firm specializing exclusively in pharmaceutical and biotech companies. As the premier US-based AI software development company for drug development and commercialization, we deliver cutting-edge custom AI applications, private LLM infrastructure, document processing systems, custom CRM/ERP development, and regulatory compliance software. Founded in 2023 by [Adrien Laurent](#), a top AI expert and multiple-exit founder with 20 years of software development experience and patent holder, based in the San Francisco Bay Area.

This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.

© 2025 IntuitionLabs.ai. All rights reserved.